Thrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
|
|
- Horace O’Brien’
- 5 years ago
- Views:
Transcription
1 Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women s Hospital Harvard Medical School Boston, MA 1
2 Disclosures Research Support: Daiichi Sankyo, AstraZeneca, Bristol-Meyers Squibb, Sanofi-Aventis Consultant: Alere and Beckman Coulter 2
3 Atrial Fibrillation: An Epidemic Projected Number of People with AF (millions) US Prevalence 16 million 1 in 4 lifetime risk in men and women 40 years old Based on Projected Incidence Miyakasa Y, et al. Circulation. 2006; 114: Year 3
4 Complications of AF Embolic Stroke Hemodynamic Fatigue Shortness of Breath Systemic Embolism Palpitations CHF 4
5 % Stroke in AF Approximately 5X increased risk of stroke Risk varies significantly depending on clinical factors Embolic strokes from AF have worse outcomes Substantial morbidity and mortality Staggering health care costs ~ $16 billion/year Framingham AF prevalence Strokes attributable to AF Wolf PA, et al. Stroke 1991; 22: Age Range (years) 5
6 Treatment of AF Antithrombotic Therapy Rhythm Control Rate Control 6
7 Antithrombotic Therapy Antithrombotic Therapy Antiplatelet Anticoagulant 7
8 Stroke Prevention in AF Warfarin vs. Aspirin AFASAK I (432) AFASAK II (439) EAFT (403) PATAF (443) SPAF II (440) All Trials (n=5) 33% 100% 50% 0% -50% -100% Warfarin Better Aspirin Better Fuster V, et al. Circulation 2011;123:e
9 CHADS 2 Risk Score Risk Factor Points Congestive Heart Failure 1 Hypertension 1 Age 75 1 Diabetes Mellitus 1 Stroke or TIA 2 Maximum Score 6 CHADS 2 Stroke (% / yr) Gage BF, et al. JAMA. 2001;285: VanWalraven C, et al. Arch Intern Med 2003; 163:936. Nieuwlaat R, et al. (EuroHeart survey) Eur Heart J 2006 (E-published). Go A, et al. JAMA 2003; 290: Gage BF, et al. Circulation 2004; 110:
10 Risk Stratification Threshold for Anticoagulation CHADS 2 Risk of Stroke (%/yr) %/year Van Walraven C, et al. Arch Intern Med 2003; 163:936. Go A, et al. JAMA 2003; 290: Gage BF, et al. Circulation 2004; 110: 2287.
11 Prior ACC/AHA/ESC Guidelines Risk Factor No risk factors CHADS 2 = 0 One moderate risk factor CHADS 2 = 1 Any high risk factor or >1 moderate risk factor CHADS 2 >2 Prosthetic valve Recommended Therapy Aspirin, mg Aspirin, mg or Warfarin (INR , target 2.5) Warfarin (INR , target 2.5) Warfarin (INR , target 3.0) 11
12 CHADS 2 Risk Score Score (points) Prevalence (%) Congestive Heart failure 1 32 Hypertension 1 65 Age >75 years 1 28 Diabetes mellitus 1 18 Stroke or TIA 2 10 Moderate-High risk > Low risk VanWalraven C, et al. Arch Intern Med 2003; 163:936. Nieuwlaat R, et al. (EuroHeart survey) Eur Heart J 2006 (E-published). Gage BF, et al. JAMA. 2001;285:
13 Redefining Benefit: CHA 2 DS 2 -VASc Risk Factor Points CHF / LV Dysfunction 1 Hypertension 1 Age 75 2 Diabetes Mellitus 1 Stroke / TIA / Embolism 2 Vascular Disease 1 Age Sex Category (female) 1 Maximum Score 9 CHA 2 DS 2 -VASc Score Stroke (% / yr) 1 0 % % % % % % % % % ESC Guidelines: Eur Heart J. 2010;31:
14 Redefining Risk: HAS-BLED Letter Clinical Characteristic Points H Hypertension 1 A Abnormal Liver or Renal Function 1 or 2 S Stroke 1 B Bleeding 1 L Labile INR 1 E Elderly (age > 65) 1 D Drugs or Alcohol 1 or 2 HAS-BLED Score Stroke (% / yr) ? Lip GYH. Am J Med. 2011;124: Maximum Score 9 ESC Guidelines: Eur Heart J. 2010;31:
15 Net Clinical Benefit of Warfarin All-Cause Mortality, Ischemic Stroke, & ICH Friberg L, et al. Circulation 2012; 125:
16 Stroke Prevention Recommendations Fuster V, Chinitz JS. Circulation 2012; 125:
17 The Future Biomarkers RE-LY Stroke, SEE, PE, MI, & Vascular Death Trop NTproBNP Hijazi Z, et al. Circulation 2012; 125: Trop NTproBNP 17
18 The Future Genetics 4q25 Variant Only Predicts Cardioembolic Stroke HR 1.48 ( ) Lemmens R, et al. Stroke 2010; 41:
19 Conclusions Risk Stratification The decision to prescribe anticoagulant therapy to a patient with AF requires balancing their individual risk of stroke and potential for bleeding complications. There will be refinement of risk prediction strategies (CHA 2 DS 2 -VASc, HAS-BLED, addition of biomarkers/genetics) that will result in a greater proportion of patients being eligible for anticoagulation. 19
20 History of Warfarin 20
21 Limitations of Warfarin Delayed onset/offset Multiple food and drug interactions Genetic variability in metabolism (VKORC1 and CYP2C9) Requires frequent monitoring of INR due to limited therapeutic index 21
22 Preventable Strokes AF Patients with Stroke with no Known Contraindication to Anticoagulation No warfarin 61% INR in range 10% Subtherapeutic INR 29% Gladston, DJ, et al. Stroke 2009;40:
23 Properties of an Ideal Anticoagulant Properties Oral, once daily dosing Rapid onset of action Minimal food or drug interactions Predictable anticoagulant effect Extra renal clearance Rapid offset in action Antidote Benefit Ease of administration No need for overlapping parenteral anticoagulant Simplified dosing No coagulation monitoring Safe in patients with renal disease Simplifies management in case of bleeding or intervention For emergencies 23
24 Novel Oral Anticoagulants TTP889 TF/VIIa Dabigatran AZD0837 MCC 977 X Fibrinogen IX IXa VIIIa Va Xa II IIa Fibrin Rivaroxaban Apixaban Edoxaban Betrixaban Eribaxaban Razaxaban YM150 LY TAK 442 Adapted from: Weitz JI, Bates SM. J Thromb Haemost 2005;3:
25 Major Advances In Oral Anticoagulation for SPAF 6 Trial of Warfarin vs. Placebo ROCKET AF (Rivaroxaban) 2010 ENGAGE AF (Edoxaban)? RE-LY (Dabigatran) 2009 ARISTOTLE (Apixaban)
26 RE-LY Atrial fibrillation 1 Risk Factor Absence of contra-indications 951 centers in 44 countries PROBE=Prospective Randomized Open Trial with Blinded Adjudication of Events. R open Blinded Warfarin (INR ) N=6022 Dabigatran Etexilate 110 mg b.i.d. N=6015 Dabigatran Etexilate 150 mg b.i.d. N= efficacy outcome = stroke or systemic embolism 1 0 safety outcome = major bleeding Non-inferiority margin
27 RE-LY Efficacy: Stroke/SEE Non-inferiority p-value Superiority p-value Dabigatran 110 vs. Warfarin < Dabigatran 150 vs. Warfarin <0.001 <0.001 Margin = 1.46 Connolly, et al. N Engl J Med 2009;361: HR (95% CI) 27
28 RE-LY Efficacy Dabigatran 110 mg Dabigatran 150 mg Stroke/SEE 0.91 ( ) 0.66 ( ) Ischemic Stroke 1.11 ( ) 0.76 ( ) Hemorrhagic Stroke 0.31 ( ) 0.26 ( ) Connolly, et al. N Engl J Med 2009;361: Dabigatran Better Warfarin Better 28
29 RE-LY Safety Dabigatran 110 mg Dabigatran 150 mg Major Bleed 0.80 ( ) 0.93 ( ) ICH 0.31 ( ) 0.40 ( ) GI Bleed 1.10 ( ) 1.50 ( ) MI 1.29 ( ) 1.27 ( ) Connolly, et al. N Engl J Med 2009;361: Dabigatran Better Warfarin Better 29
30 RE-LY Efficacy Stratified by CHADS 2 Annualized Rate Stroke/SEE (%) D110 D150 CHADS 2 D110 D150 WARF P = 0.44 P = Dabigatran Warfarin better better Dabigatran better Warfarin better Oldgren J, et al. ACC
31 RE-LY Efficacy Stratified by Prior VKA Ezekowitz MD, et al. Circulation 2010;122:
32 Dabigatran Approval Prevention of stroke in AF Available in 75 mg and 150 mg (twice daily) Dose of 75 mg if CrCl ml/min Data in favor of 110 mg were suggestive, but not entirely convincing 32
33 Atrial Fibrillation Risk Factors CHF At least 2 Hypertension required Age 75 Diabetes OR Stroke, TIA or Systemic embolus Rivaroxaban 20 mg daily 15 mg for Cr Cl Randomize Double blind / Double Dummy (n=14,266) Warfarin INR target ( inclusive) Monthly Monitoring and adherence to standard of care guidelines Primary Endpoint: Stroke or non-cns Systemic Embolism Statistics: non-inferiority, >95% power, 2.3% warfarin event rate 33
34 ROCKET AF Efficacy: Stroke/SEE Rivaroxaban Warfarin Event Rate Event Rate HR (95% CI) P-value On Treatment N=14, (0.65, 0.95) ITT N=14, (0.74, 1.03) Rivaroxaban better Warfarin better Event Rates are per 100 patient-years Based on Safety on Treatment or Intention-to-Treat thru Site Notification populations Patel, et al. N Engl J Med 2011;365(10);
35 ROCKET AF Key Secondary Efficacy Event Rivaroxaban (%/yr) Warfarin (%/yr) Hazarard Ratio (95% CI) P- value Ischemic Stroke ( ) Hemorrhagic Stroke ( ) MI ( ) Total Mortality ( ) Vascular Mortality ( ) Patel, et al. N Engl J Med 2011; 365(10);
36 ROCKET AF Safety Event Rivaroxaban (%/yr) Warfarin (%/yr) Hazarard Ratio (95% CI) P- value Major & Clinically Relevant Bleed ( ) 0.44 Major Bleed ( ) 0.58 Fatal Bleed ( ) ICH ( ) 0.02 Patel, et al. N Engl J Med 2011; 365(10);
37 Rivaroxaban Approval Prevention of stroke in AF Dose 20 mg if CrCl >50 ml/min Dose of 15 mg if CrCl ml/min 37
38 Atrial Fibrillation with at Least One Additional Risk Factor for Stroke Inclusion risk factors Age 75 years Prior stroke, TIA or SE HF or LVEF 40% Diabetes mellitus Hypertension Randomize double blind, double dummy (n = 18,201) Exclusion Mechanical prosthetic valve Severe renal insufficiency Need for aspirin plus thienopyridine Apixaban 5 mg oral twice daily (2.5 mg BID in selected patients) Warfarin (target INR 2-3) Warfarin/warfarin placebo adjusted by INR/sham INR based on encrypted point-of-care testing device Primary outcome: stroke or systemic embolism Hierarchical testing: non-inferiority for primary outcome, superiority for primary outcome, major bleeding, death
39 ARISTOTLE Efficacy: Stroke/SEE HR 0.79 ( ) (1.60 %/yr) 21% RRR (1.27 %/yr ) P (non-inferiority) <0.001 P (superiority) =0.011 Granger CB, et al. NEJM 2011; 365:
40 ARISTOTLE Key Secondary Efficacy Event Apixaban (%/yr) Warfarin (%/yr) Hazarard Ratio (95% CI) P- value Ischemic Stroke ( ) 0.42 Hemorrhagic Stroke (0.35, 0.75) <0.001 MI (0.66, 1.17) 0.37 Total Mortality ( ) Stroke/SEE/Total Mortality ( ) Granger CB, et al. NEJM 2011; 365:
41 ARISTOTLE Safety Event Rivaroxaban (%/yr) Warfarin (%/yr) Hazarard Ratio (95% CI) P- value ISTH Major Bleeding ( ) <0.001 ICH ( ) <0.001 GUSTO Severe ( ) <0.001 Gastrointestinal ( ) 0.37 Granger CB, et al. NEJM 2011; 365:
42 Phase III: Protocol Schema N = 21,105 DOUBLE BLIND DOUBLE DUMMY AF on Electrical Recording <12 mo Intended oral A/C CHADS 2 >2 R Randomization Stratified By 1. CHADS vs Drug Clearance Low dose regimen Edoxaban 30 mg QD (n 7000) High dose regimen Edoxaban 60 mg QD (n 7000) Active Control Warfarin (n 7000) Median Duration of Follow-up 24 months Primary Objective Edoxaban: Therapeutically as Good as Warfarin 1º EP = Stroke or SEE (Noninferiority Boundary HR 1.38) 2º EP = Stroke or SEE or CV mortality Safety EP s = Major Bleeding, Hepatic Function EVENT DRIVEN SEE = systemic embolic event Ruff CR et al. Am Heart J 2010; 160:635-41
43 Baseline Characteristics in AF Trials RE-LY (Dabigatran) ARISTOTLE (Apixaban) ENGAGE AF-TIMI 48* (Edoxaban) ROCKET-AF (Rivaroxaban) # Enrolled 18,113 18,201 21,105 14,264 Age (yrs) 72 ± 9 70 [63-76] 72 [64-77] 73 [65-78] Female 36% 35% 38% 40% CHADS 2 score 3 32% 30% 52% 87% VKA naive 50% 43% 41% 38% Paroxysmal AF 33% 15% 25% 18% Prior stroke/tia 20% 19% 18% / 12% 55%** Diabetes 23% 25% 36% 40% Prior CHF 32% 35% 56% 62% Hypertension 79% 87% 90% 91% *Preliminary data **includes prior systemic embolism Connolly SJ et al. N Engl J Med 2009; 361: Patel MR et al. N Engl J Med 2011; 365: Granger CB et al. N Engl J Med 2011; 365: Ruff CR et al. Am Heart J 2010; 160:
44 AF Trials Dose Comparison RE-LY ROCKET-AF ARISTOTLE ENGAGE AF-TIMI 48 Drug Dabigatran Rivaroxaban Apixaban Edoxaban N 18,113 14,266 18,201 21,105 Dose (mg) Frequency 150, 110 BID 20 QD 5 BID Initial Dose adj* No mg mg 60, 30 QD mg mg Dose adj (%) >25 Dose adj* after randomization No No No Yes Design PROBE 2x blind 2x blind 2x blind *Dose adjusted in patients with drug clearance. PROBE = prospective, randomized, open-label, blinded end point evaluation Connolly SJ et al. N Engl J Med 2009; 361: Patel MR et al. N Engl J Med 2011; 365: Granger CB et al. N Engl J Med 2011; 365: Ruff CR et al. Am Heart J 2010; 160:
45 AF Trials: Results To Date RE-LY ROCKET-AF ARISTOTLE Drug Dose (mg) Dabigatran 110 BID 150 BID Rivaroxaban 20 mg QD Apixaban 5 mg BID Stroke + SEE non-infer Superior ITT cohort: non-infer. On Rx cohort: Superior Superior ICH Superior Superior Superior Superior Bleeding Lower similar similar Lower Mortality similar p=0.051 similar Superior: p=0.047 Ischemic stroke similar Lower similar similar Mean TTR 64% 55% 62% Stopped drug 21% 23% 23% WD consent 2.3% 8.7% 1.1% TTR = time in therapeutic range WD consent = withdrawal of consent, no further data available 45
46 Efficacy of New Oral Anticoagulants Stroke & SEE Ischemic & Unsp. Stroke 13% Hemorraghic Stroke 55% Favors NOACs Miller CS, et al. Am J Cardiol 2012;110(3): Favors Warfarin 46
47 Safety of New Oral Anticoagulants Bleeding Major ICH 51% GI Favors NOACs Miller CS, et al. Am J Cardiol 2012;110(3): Favors Warfarin 47
48 Does INR Matter? Treatment Group Event Rate / Year Warfarin Event Rate / Year p-value (interaction) ROCKET AF % % % % RE-LY (Dabigatran 150 mg) 0.20 <57.1% % % >72.6% ARISTOTLE 0.29 < 58.0% % % > 72.2 % Wallentin L, et al. Lancet 2010;376: Patel, et al. NEJM 2011;365(10); Granger CB, et al. NEJM 2011; 365: Hazard Ratio (95% CI) Study Drug Favors Warfarin
49 Novel Oral Anticoagulants Discontinuation of Drug Problem Rivaroxaban Warfarin Event Rate Event Rate HR (95% CI) P-value On Treatment N=14, (0.65, 0.95) ITT N=14, (0.74, 1.03) Rivaroxaban better Warfarin better Event Rates are per 100 patient-years Based on Safety on Treatment or Intention-to-Treat thru Site Notification populations Patel, et al. N Engl J Med 2011;365(10);
50 NOACs: More Events Off-Drug 3 13% 25% %/yr 1.7 Rivaroxaban Warfarin 1 P=0.015 P= On Treatment ITT 50
51 ESC 2012 AF Guidelines Update Risk Profile Class / Level CHA 2 DS 2 -VASc = 0 No antithrombotic therapy I B CHA 2 DS 2 -VASc = 1 CHA 2 DS 2 -VASc 2 VKA (INR 2-3) Or Dabigatran / Rivaroxaban / Apixaban IIa A VKA (INR 2-3) Or Dabigatran / Rivaroxaban / Apixaban I A 51
52 Issues & Limitations in Clinical Practice Potential Risks of Major Bleeding in Elderly 1,2 and patients with CKD 3 Low body weight and decreased renal function increase drug exposure Increased Risk of Bleeding with AF Ablation 4 Compared with warfarin, periprocedural use increases risk of bleeding Poor Outcomes Following Trauma 5 No method readily available to determine degree of anticoagulation & no antidote High Rates of Early Discontinuation 6 Cost effectiveness? 1 Legrand. M Arch Intern Med 2011; 171: Harper P. N Eng J Med 2012; 366: Olesen J. N Eng J Med 2012; 367: Lakkireddy D. JACC 2012; 59:1-7 5 Cotton B. N Eng J Med 2011; 365: Stanek E. Circulation 2011; 124:A
53 Conclusions New therapies provide the promise of providing safer and more convenient anticoagulation. There are important differences in the PK/PD of these agents (half-life, metabolism, renal elimination) that will alter the risk/benefit profile in specific populations. The development of a clinically tested reversal agent is necessary before widespread adoption. There will be refinement of risk prediction strategies (CHA 2 DS 2 -VASc, HAS-BLED) that will result in a greater proportion of patients being eligible for anticoagulation. 53
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationNew Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationConflict of interest statement
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationArrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies
Arrhythmias and Clinical EP Contemporary Management of Anticoagulant Therapies Samuel Asirvatham, MD & Ivan Mendoza, MD Saturday, June 24, 2017 11:15 a.m. to 12 p.m. Disclosures Relevant financial relationship(s)
More informationDr. Khalid Khan Consultant Cardiologist
Dr. Khalid Khan Consultant Cardiologist BCUHB (Wrexham) WCS Spring Meeting 2012 When the pulse is irregular and tremulous and the beats occur at intervals, then the impulse of life fades; when the pulse
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationAtrial Fibrillation. E. Kevin Heist, MD, PhD. Updates in General Internal Medicine for Specialists January 28, 2019
Atrial Fibrillation E. Kevin Heist, MD, PhD Updates in General Internal Medicine for Specialists January 28, 2019 Disclosures Abbott Consultant, Research Grant Biotronik Consultant Boston Scientific Consultant
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationRelationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial
Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Jonathan P. Piccini, Frank Harrell, Yulia Lokhnygina,
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationModern Management in Primary Care (AF1)
Modern Management in Primary Care (AF1) Dr Ravi Assomull Consultant Cardiologist London North West Healthcare NHS Trust Dr Yassir Javaid Primary Care Cardiovascular Lead East Midlands Strategic Clinical
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationDisclosures for Albert L. Waldo, M.D.
Alternative Anticoagulation Stgies in Atrial Fibrillation: Issues and Answers? Albert L. Waldo, MD The Walter H. Pritchard Professor of Cardiology, Professor of Medicine, and Professor of Biomedical Engineering
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More information